|
Dear Reader,
A rare government designation was recently issued to a leading “the race to a cure” (as seen in the image below)
 The FDA hands out this rare classification “to provide lucrative incentives to the drug’s maker,” says NPR.
And The Intercept says “the designation allows for the pharmaceutical company to profit exclusively for seven years from the product.”
What does this mean for the stock?
If history is any indication…
This rare designation is responsible for helping Vertex’ launch from $35 to $235…
 A 571% gain…
And Alexion skyrocket from $22 to $200…
 That’s an 809% gain…
Get the full breakdown of what this important designation could do to this new stock, by clicking here.
Matt Benjamin
Senior Macroeconomic Analyst, The Oxford Club
P.S. A critical data announcement is expected this month that could turboboost the stock to the moon.
Get the urgent details by clicking here. |